Intrinsic value of Intrexon - XON

Previous Close

$18.21

  Intrinsic Value

$0.88

stock screener

  Rating & Target

str. sell

-95%

  Value-price divergence*

+117%

Previous close

$18.21

 
Intrinsic value

$0.88

 
Up/down potential

-95%

 
Rating

str. sell

 
Value-price divergence*

+117%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of XON stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  9.77
  25.60
  23.54
  21.69
  20.02
  18.52
  17.16
  15.95
  14.85
  13.87
  12.98
  12.18
  11.46
  10.82
  10.24
  9.71
  9.24
  8.82
  8.44
  8.09
  7.78
  7.50
  7.25
  7.03
  6.83
  6.64
  6.48
  6.33
  6.20
  6.08
  5.97
Revenue, $m
  191
  240
  296
  361
  433
  513
  601
  697
  800
  911
  1,030
  1,155
  1,288
  1,427
  1,573
  1,726
  1,885
  2,051
  2,224
  2,404
  2,591
  2,786
  2,988
  3,198
  3,416
  3,643
  3,879
  4,125
  4,381
  4,647
  4,924
Variable operating expenses, $m
 
  437
  536
  649
  776
  916
  1,071
  1,239
  1,421
  1,616
  1,824
  2,028
  2,261
  2,505
  2,762
  3,030
  3,310
  3,602
  3,906
  4,222
  4,550
  4,892
  5,246
  5,615
  5,998
  6,397
  6,811
  7,243
  7,692
  8,159
  8,646
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  316
  437
  536
  649
  776
  916
  1,071
  1,239
  1,421
  1,616
  1,824
  2,028
  2,261
  2,505
  2,762
  3,030
  3,310
  3,602
  3,906
  4,222
  4,550
  4,892
  5,246
  5,615
  5,998
  6,397
  6,811
  7,243
  7,692
  8,159
  8,646
Operating income, $m
  -125
  -197
  -240
  -288
  -343
  -403
  -470
  -542
  -621
  -705
  -794
  -873
  -973
  -1,078
  -1,189
  -1,304
  -1,425
  -1,550
  -1,681
  -1,817
  -1,959
  -2,106
  -2,258
  -2,417
  -2,582
  -2,754
  -2,932
  -3,118
  -3,311
  -3,512
  -3,722
EBITDA, $m
  -100
  -161
  -199
  -242
  -291
  -345
  -404
  -468
  -538
  -612
  -692
  -776
  -865
  -958
  -1,056
  -1,159
  -1,266
  -1,378
  -1,494
  -1,615
  -1,740
  -1,871
  -2,007
  -2,148
  -2,294
  -2,447
  -2,605
  -2,770
  -2,942
  -3,121
  -3,307
Interest expense (income), $m
  1
  1
  12
  25
  39
  56
  74
  93
  115
  138
  164
  190
  219
  248
  280
  313
  347
  383
  421
  460
  501
  543
  587
  632
  680
  729
  780
  833
  889
  947
  1,007
Earnings before tax, $m
  -173
  -198
  -252
  -313
  -382
  -459
  -544
  -636
  -736
  -843
  -957
  -1,063
  -1,192
  -1,327
  -1,469
  -1,617
  -1,772
  -1,934
  -2,102
  -2,277
  -2,459
  -2,648
  -2,845
  -3,049
  -3,262
  -3,483
  -3,712
  -3,951
  -4,200
  -4,459
  -4,729
Tax expense, $m
  -4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -187
  -198
  -252
  -313
  -382
  -459
  -544
  -636
  -736
  -843
  -957
  -1,063
  -1,192
  -1,327
  -1,469
  -1,617
  -1,772
  -1,934
  -2,102
  -2,277
  -2,459
  -2,648
  -2,845
  -3,049
  -3,262
  -3,483
  -3,712
  -3,951
  -4,200
  -4,459
  -4,729

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  237
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  949
  895
  1,106
  1,346
  1,615
  1,914
  2,243
  2,600
  2,986
  3,401
  3,842
  4,310
  4,804
  5,324
  5,869
  6,439
  7,034
  7,654
  8,300
  8,971
  9,670
  10,395
  11,149
  11,933
  12,748
  13,594
  14,475
  15,392
  16,346
  17,339
  18,374
Adjusted assets (=assets-cash), $m
  712
  895
  1,106
  1,346
  1,615
  1,914
  2,243
  2,600
  2,986
  3,401
  3,842
  4,310
  4,804
  5,324
  5,869
  6,439
  7,034
  7,654
  8,300
  8,971
  9,670
  10,395
  11,149
  11,933
  12,748
  13,594
  14,475
  15,392
  16,346
  17,339
  18,374
Revenue / Adjusted assets
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
  0.268
Average production assets, $m
  291
  366
  452
  550
  660
  782
  916
  1,062
  1,220
  1,389
  1,569
  1,760
  1,962
  2,174
  2,397
  2,630
  2,873
  3,126
  3,390
  3,664
  3,949
  4,246
  4,554
  4,874
  5,207
  5,552
  5,912
  6,286
  6,676
  7,082
  7,505
Working capital, $m
  220
  -20
  -25
  -30
  -36
  -43
  -50
  -59
  -67
  -77
  -86
  -97
  -108
  -120
  -132
  -145
  -158
  -172
  -187
  -202
  -218
  -234
  -251
  -269
  -287
  -306
  -326
  -346
  -368
  -390
  -414
Total debt, $m
  9
  108
  223
  353
  500
  663
  842
  1,037
  1,248
  1,473
  1,714
  1,969
  2,238
  2,522
  2,819
  3,129
  3,454
  3,792
  4,143
  4,509
  4,890
  5,285
  5,696
  6,124
  6,567
  7,029
  7,509
  8,008
  8,528
  9,070
  9,634
Total liabilities, $m
  389
  488
  603
  733
  880
  1,043
  1,222
  1,417
  1,628
  1,853
  2,094
  2,349
  2,618
  2,902
  3,199
  3,509
  3,834
  4,172
  4,523
  4,889
  5,270
  5,665
  6,076
  6,504
  6,947
  7,409
  7,889
  8,388
  8,908
  9,450
  10,014
Total equity, $m
  560
  407
  503
  612
  735
  871
  1,020
  1,183
  1,359
  1,547
  1,748
  1,961
  2,186
  2,422
  2,670
  2,930
  3,200
  3,483
  3,776
  4,082
  4,400
  4,730
  5,073
  5,430
  5,800
  6,185
  6,586
  7,003
  7,437
  7,889
  8,360
Total liabilities and equity, $m
  949
  895
  1,106
  1,345
  1,615
  1,914
  2,242
  2,600
  2,987
  3,400
  3,842
  4,310
  4,804
  5,324
  5,869
  6,439
  7,034
  7,655
  8,299
  8,971
  9,670
  10,395
  11,149
  11,934
  12,747
  13,594
  14,475
  15,391
  16,345
  17,339
  18,374
Debt-to-equity ratio
  0.016
  0.260
  0.440
  0.580
  0.680
  0.760
  0.830
  0.880
  0.920
  0.950
  0.980
  1.000
  1.020
  1.040
  1.060
  1.070
  1.080
  1.090
  1.100
  1.100
  1.110
  1.120
  1.120
  1.130
  1.130
  1.140
  1.140
  1.140
  1.150
  1.150
  1.150
Adjusted equity ratio
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455
  0.455

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -187
  -198
  -252
  -313
  -382
  -459
  -544
  -636
  -736
  -843
  -957
  -1,063
  -1,192
  -1,327
  -1,469
  -1,617
  -1,772
  -1,934
  -2,102
  -2,277
  -2,459
  -2,648
  -2,845
  -3,049
  -3,262
  -3,483
  -3,712
  -3,951
  -4,200
  -4,459
  -4,729
Depreciation, amort., depletion, $m
  25
  36
  41
  46
  52
  59
  66
  74
  83
  92
  102
  97
  108
  120
  132
  145
  159
  173
  187
  202
  218
  235
  252
  269
  288
  307
  327
  347
  369
  391
  415
Funds from operations, $m
  -67
  -162
  -211
  -267
  -330
  -400
  -477
  -562
  -653
  -751
  -855
  -966
  -1,083
  -1,207
  -1,336
  -1,472
  -1,613
  -1,761
  -1,915
  -2,075
  -2,241
  -2,414
  -2,593
  -2,780
  -2,974
  -3,176
  -3,386
  -3,604
  -3,831
  -4,068
  -4,314
Change in working capital, $m
  -11
  -4
  -5
  -5
  -6
  -7
  -7
  -8
  -9
  -9
  -10
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -15
  -15
  -16
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -21
  -22
  -23
Cash from operations, $m
  -56
  -158
  -206
  -262
  -324
  -393
  -470
  -553
  -644
  -741
  -845
  -955
  -1,072
  -1,195
  -1,324
  -1,459
  -1,600
  -1,747
  -1,900
  -2,060
  -2,225
  -2,398
  -2,576
  -2,762
  -2,956
  -3,157
  -3,366
  -3,583
  -3,810
  -4,045
  -4,291
Maintenance CAPEX, $m
  0
  -16
  -20
  -25
  -30
  -36
  -43
  -51
  -59
  -67
  -77
  -87
  -97
  -108
  -120
  -132
  -145
  -159
  -173
  -187
  -202
  -218
  -235
  -252
  -269
  -288
  -307
  -327
  -347
  -369
  -391
New CAPEX, $m
  -39
  -75
  -86
  -98
  -110
  -122
  -134
  -146
  -158
  -169
  -180
  -191
  -202
  -212
  -223
  -233
  -243
  -253
  -264
  -274
  -285
  -296
  -308
  -320
  -333
  -346
  -360
  -374
  -390
  -406
  -423
Cash from investing activities, $m
  -28
  -91
  -106
  -123
  -140
  -158
  -177
  -197
  -217
  -236
  -257
  -278
  -299
  -320
  -343
  -365
  -388
  -412
  -437
  -461
  -487
  -514
  -543
  -572
  -602
  -634
  -667
  -701
  -737
  -775
  -814
Free cash flow, $m
  -84
  -249
  -313
  -384
  -464
  -552
  -647
  -750
  -860
  -978
  -1,102
  -1,233
  -1,371
  -1,516
  -1,667
  -1,824
  -1,988
  -2,159
  -2,337
  -2,521
  -2,713
  -2,912
  -3,119
  -3,334
  -3,558
  -3,790
  -4,032
  -4,284
  -4,546
  -4,820
  -5,105
Issuance/(repayment) of debt, $m
  0
  100
  115
  131
  147
  163
  179
  195
  210
  226
  241
  255
  269
  283
  297
  311
  324
  338
  352
  366
  381
  395
  411
  427
  444
  462
  480
  499
  520
  541
  564
Issuance/(repurchase) of shares, $m
  19
  281
  348
  422
  505
  595
  693
  799
  911
  1,031
  1,158
  1,276
  1,417
  1,563
  1,717
  1,876
  2,043
  2,216
  2,396
  2,583
  2,777
  2,979
  3,188
  3,406
  3,632
  3,868
  4,113
  4,368
  4,634
  4,911
  5,200
Cash from financing (excl. dividends), $m  
  12
  381
  463
  553
  652
  758
  872
  994
  1,121
  1,257
  1,399
  1,531
  1,686
  1,846
  2,014
  2,187
  2,367
  2,554
  2,748
  2,949
  3,158
  3,374
  3,599
  3,833
  4,076
  4,330
  4,593
  4,867
  5,154
  5,452
  5,764
Total cash flow (excl. dividends), $m
  -73
  132
  150
  168
  187
  206
  225
  243
  262
  279
  297
  298
  315
  331
  347
  363
  379
  395
  411
  428
  445
  462
  480
  499
  519
  539
  561
  583
  607
  633
  659
Retained Cash Flow (-), $m
  134
  -281
  -348
  -422
  -505
  -595
  -693
  -799
  -911
  -1,031
  -1,158
  -1,276
  -1,417
  -1,563
  -1,717
  -1,876
  -2,043
  -2,216
  -2,396
  -2,583
  -2,777
  -2,979
  -3,188
  -3,406
  -3,632
  -3,868
  -4,113
  -4,368
  -4,634
  -4,911
  -5,200
Prev. year cash balance distribution, $m
 
  236
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  87
  -198
  -254
  -317
  -389
  -468
  -555
  -650
  -752
  -862
  -978
  -1,102
  -1,232
  -1,370
  -1,514
  -1,664
  -1,821
  -1,985
  -2,155
  -2,332
  -2,517
  -2,708
  -2,907
  -3,114
  -3,329
  -3,552
  -3,785
  -4,027
  -4,278
  -4,541
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  84
  -181
  -221
  -261
  -301
  -340
  -375
  -406
  -432
  -452
  -465
  -470
  -469
  -460
  -444
  -423
  -396
  -366
  -332
  -296
  -260
  -225
  -191
  -159
  -129
  -104
  -81
  -62
  -47
  -34
Current shareholders' claim on cash, %
  100
  81.2
  66.1
  54.0
  44.3
  36.4
  30.0
  24.8
  20.6
  17.1
  14.3
  11.9
  10.0
  8.4
  7.1
  5.9
  5.0
  4.2
  3.6
  3.0
  2.6
  2.2
  1.8
  1.6
  1.3
  1.1
  1.0
  0.8
  0.7
  0.6
  0.5

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; RheoSwitch inducible gene switch; Cell Systems Informatics; AttSite Recombinases; Protein Engineering; antibody discovery; LEAP processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor altering chemical or antioxidant additives; and commercial aquaculture products. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

FINANCIAL RATIOS  of  Intrexon (XON)

Valuation Ratios
P/E Ratio -11.6
Price to Sales 11.3
Price to Book 3.9
Price to Tangible Book
Price to Cash Flow -38.6
Price to Free Cash Flow -22.8
Growth Rates
Sales Growth Rate 9.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate 81.1%
Financial Strength
Quick Ratio 237
Current Ratio 0.1
LT Debt to Equity 1.4%
Total Debt to Equity 1.6%
Interest Coverage -172
Management Effectiveness
Return On Assets -19.3%
Ret/ On Assets - 3 Yr. Avg. -15.2%
Return On Total Capital -29.4%
Ret/ On T. Cap. - 3 Yr. Avg. -22%
Return On Equity -29.8%
Return On Equity - 3 Yr. Avg. -22.4%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 67.5%
Gross Margin - 3 Yr. Avg. 73.2%
EBITDA Margin -77%
EBITDA Margin - 3 Yr. Avg. -69.4%
Operating Margin -65.4%
Oper. Margin - 3 Yr. Avg. -82.2%
Pre-Tax Margin -90.6%
Pre-Tax Margin - 3 Yr. Avg. -82.2%
Net Profit Margin -97.9%
Net Profit Margin - 3 Yr. Avg. -86.7%
Effective Tax Rate 2.3%
Eff/ Tax Rate - 3 Yr. Avg. 0.3%
Payout Ratio 0%

XON stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the XON stock intrinsic value calculation we used $191 million for the last fiscal year's total revenue generated by Intrexon. The default revenue input number comes from 2016 income statement of Intrexon. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our XON stock valuation model: a) initial revenue growth rate of 25.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for XON is calculated based on our internal credit rating of Intrexon, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Intrexon.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of XON stock the variable cost ratio is equal to 183.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for XON stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 11.1% for Intrexon.

Corporate tax rate of 27% is the nominal tax rate for Intrexon. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the XON stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for XON are equal to 152.4%.

Life of production assets of 18.1 years is the average useful life of capital assets used in Intrexon operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for XON is equal to -8.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $560 million for Intrexon - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 115.138 million for Intrexon is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Intrexon at the current share price and the inputted number of shares is $2.1 billion.

RELATED COMPANIES Price Int.Val. Rating
ZIOP ZIOPHARM Oncol 5.34 0.09  str.sell

COMPANY NEWS

▶ Here's How Intrexon Might Prove Me Wrong   [09:08AM  Motley Fool]
▶ Intrexon Corp. Value Analysis (NYSE:XON) : August 1, 2017   [Jul-31-17 08:12PM  Capital Cube]
▶ 3 Biggest Challenges Facing This Billionaire-Led Stock   [Jul-12-17 08:10AM  Motley Fool]
▶ 7 Wacky Sources of Alternative Energy   [06:00AM  Motley Fool]
▶ ETFs with exposure to Intrexon Corp. : July 10, 2017   [Jul-10-17 03:32PM  Capital Cube]
▶ Why Intrexon Stock Rose 10.4% in June   [12:26PM  Motley Fool]
▶ ETFs with exposure to Intrexon Corp. : June 26, 2017   [Jun-26-17 05:16PM  Capital Cube]
▶ ETFs with exposure to Intrexon Corp. : June 16, 2017   [Jun-16-17 04:27PM  Capital Cube]
▶ 3 Stocks Billionaires Own   [10:05AM  Motley Fool]
▶ How these two Tampa Bay companies got the financing to grow their technology   [May-16-17 12:18PM  American City Business Journals]
▶ Ziopharm Prices Secondary Offering   [10:40AM  24/7 Wall St.]
▶ Why Intrexon Is Soaring Today   [12:01PM  Motley Fool]
▶ Intrexon reports 1Q loss   [May-10-17 04:24PM  Associated Press]
▶ Intrexon Corp. Value Analysis (NYSE:XON) : April 27, 2017   [Apr-27-17 05:23PM  Capital Cube]
▶ Where Will Intrexon Be in 10 Years?   [Apr-18-17 11:20AM  Motley Fool]
▶ GenVec investor alleges misleading financial disclosures ahead of Intrexon acquisition   [Apr-14-17 02:34PM  American City Business Journals]
▶ 3 Stocks That Are Overvalued   [Mar-22-17 03:42PM  Motley Fool]
▶ 3 Stocks That Are Overvalued   [03:42PM  at Motley Fool]
▶ Intrexon executive out less than a year after joining the company   [Mar-13-17 03:45PM  at bizjournals.com]
▶ Can Intrexon Regain Its Mojo?   [Mar-08-17 10:09AM  at Motley Fool]
Stock chart of XON Financial statements of XON
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.